Mukai Y., Shibata H., Nakamura T., Yoshioka Y., Abe Y., Nomura T., Taniai M., Ohta T., Ikemizu S., Nakagawa S., Tsunoda S., Kamada H., Yamagata Y., Tsutsumi Y.
Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
J. Mol. Biol., 385:1221–1229, 2009. [PubMed]

Kamada H., Fugmann T., Neri D., Roesli C.
Improved protein sequence coverage by on resin deglycosylation and cysteine　modification for biomarker discovery.
Proteomics., 9(3):783-787, 2009 [PubMed]

Imai S., Yoshida Y., Okamura T., Nagano K., Abe Y., Yoshikawa T., Kamada H., Nakagawa S., Tsunoda S., Tsutsumi Y.
The specific effect of 2-Methoxyestradiol on lymphatic vascular endothelial cells.
Pharmazie., 64(3):214-6, 2009. [PubMed]

Nagano K., Imai S., Mukai Y., Nakagawa S., Abe Y., Kamada H., Tsunoda S., Tsutsumi Y.
Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library.
Pharmazie., 64(4):238-41, 2009. [PubMed]

Mukai Y., Nakamura T., Yoshioka Y., Tsunoda S., Kamada H., Nakagawa S., Yamagata Y., Tsutsumi Y.
Crystallization and preliminary X-ray analysis of TNF-TNFR2 complex.
Acta. Crystallogr. Sect. F., 65(Pt 3):295-8, 2009. [PubMed]

Yoshikawa T., Sugita T., Mukai Y., Yamanada N., Nagano K., Nabeshi H., Shibata H., Yoshioka Y., Nakagawa S., Kamada H., Tsunoda S., Tsutsumi Y.
The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains.
Biomaterials., 30(19):3318-23, 2009. [PubMed]

Mukai Y., Nakamura T., Yoshioka Y., Shibata H., Abe Y., Nomura T., Taniai M., Ohta T., Nakagawa S., Tsunoda S., Kamada H., Yamagata Y., Tsutsumi Y.
Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
J. Biochem., 146(2):167-72, 2009. [PubMed]

Kayamuro H., Yoshioka Y., Abe Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Hiroi T., Itoh N., Kawai Y., Mayumi T., Kamada H., Tsunoda S., Tsutsumi Y.
TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant.
Biochem. Biophys. Res. Commun., 384(3):296-300, 2009. [PubMed]

Nabeshi H., Yoshikawa T., Kamada H., Shibata H., Sugita T., Abe Y., Nagano K., Nomura T., Minowa K., Tsunoda S., Tsutsumi Y.
Arsenic trioxide has the inhibitory effect on transmission of human T-cell leukemia virus type 1.
Biol. Pharm. Bull., 32(7):1286-8, 2009. [PubMed]

Kayamuro H., Abe Y., Yoshioka Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Hiroi T., Itoh N., Kawai Y., Kamada H., Nagano K., Tsunoda S., Tsutsumi Y.
The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Biomaterials., 29:5869-76, 2009. [PubMed]

Nomura T., Abe Y., Kamada H., Inoue H., Kawara T., Arita S., Furuya T., Yoshioka Y., Shibata H., Kayamuro H., Yamashita T., Nagano K., Yoshikawa T., Mukai Y., Nakagawa S., Taniai M., Ohta T., Tsunoda S., Tsutsumi Y.
Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.
Biochem. Biophys. Res. Commun., 30;388(4):667-71, 2009. [PubMed]

Shibata H., Yoshioka Y., Abe Y., Ohkawa A., Nomura T., Minowa K., Mukai Y., Nakagawa S., Taniai M., Ohta T., Tsunoda S., Kamada H., Tsutsumi Y.
The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
Biomaterials., 30(34):6638-6647, 2009. [PubMed]

永田　諭志
Nagata S,* Ise T, Pastan I (2009) Fc receptor-like 3 protein expressed on IL-2 non-responsive subset of human regulatory T cells. The Journal of Immunology 182, 7518-7526. (*corresponding author)[PubMed]

Nagata S* and Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Advanced Drug Delivery Reviews, 61, 977-85. (*co-corresponding author)[PubMed]